Keyphrases
Outcome Prediction
100%
Chronic Myeloid Leukemia
100%
Tyrosine Kinase Inhibitor Therapy
100%
Conditional Survival
83%
Future Outcomes
66%
Dasatinib
50%
Survival Estimation
50%
Imatinib
33%
Nave
16%
Clinical Outcomes
16%
Phase II Study
16%
Transcript Level
16%
Imatinib Therapy
16%
Monitoring Patients
16%
Current Recommendations
16%
Background Current
16%
Survival Analysis
16%
Response Assessment
16%
Cox Proportional Hazards Model
16%
Breakpoint Cluster Region
16%
Dose Optimization
16%
Hazard Rate
16%
Calculator
16%
Nomogram
16%
Prognostic Nomogram
16%
Medicine and Dentistry
Chronic Myelogenous Leukemia
100%
Tyrosine-Kinase Inhibitor
100%
Dasatinib
60%
Imatinib
60%
Survival Estimate
60%
Clinical Trial
20%
Proportional Hazards Model
20%
Survival Analysis
20%
Prognostication
20%
Myeloid Leukemia
20%
Patient Monitoring
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Myeloid Leukemia
100%
Protein Tyrosine Kinase Inhibitor
100%
Imatinib
60%
Dasatinib
60%
Clinical Trial
20%
Myeloid Leukemia
20%